Borm, Lars E. http://orcid.org/0000-0002-1764-6057
Mossi Albiach, Alejandro
Mannens, Camiel C. A. http://orcid.org/0000-0002-1318-2603
Janusauskas, Jokubas http://orcid.org/0000-0002-9128-4218
Özgün, Ceren
Fernández-García, David http://orcid.org/0000-0002-0232-8478
Hodge, Rebecca http://orcid.org/0000-0002-5784-9668
Castillo, Francisca
Hedin, Charlotte R. H. http://orcid.org/0000-0002-4921-8516
Villablanca, Eduardo J.
Uhlén, Per http://orcid.org/0000-0003-1446-1062
Lein, Ed S. http://orcid.org/0000-0001-9012-6552
Codeluppi, Simone http://orcid.org/0000-0002-7053-0520
Linnarsson, Sten http://orcid.org/0000-0002-3491-3444
Funding for this research was provided by:
Stiftelsen för Strategisk Forskning (SB16-0065)
Knut och Alice Wallenbergs Stiftelse (2015.0041, 2018.0172, 2018.0220)
U.S. Department of Health & Human Services | National Institutes of Health (MH114812-02)
Familjen Erling-Perssons Stiftelse (HDCA)
Torsten Söderbergs Stiftelse
Article History
Received: 12 January 2022
Accepted: 1 August 2022
First Online: 22 September 2022
Competing interests
: The authors declare the following competing financial interests: L.E.B., A.M.A., C.M., J.J., D.F.G., S.C. and S.L. are shareholders in EEL Transcriptomics AB, which owns intellectual property rights to the EEL method, including a patent application with L.E.B., S.C. and S.L. as co-inventors. S.L. is a paid scientific advisor to and S.C. is a current employee of Rebus Biosystems, which has licensed the EEL intellectual property rights. The remaining authors declare no competing interests.